Results 111 to 120 of about 30,689 (278)

STAT6 controls the number of regulatory T cells in vivo, thereby regulating allergic lung inflammation. [PDF]

open access: yes, 2013
STAT6 plays a central role in IL-4-mediated allergic responses. Several studies indicate that regulatory T cells (Tregs) can be modulated by IL-4 in vitro.
Smith, Elizabeth   +5 more
core   +1 more source

Autosomal Dominant Hyper‐IgE Syndrome Patients Retain IL10‐Producing preTh17‐Cells That Are Activated by Opportunistic Pathogens and Support IgE Production

open access: yesAllergy, EarlyView.
IL‐10 producing CCR6+Th‐cells are central memory T‐cells that express ROR‐γt and differentiate to Th17‐cells via an autocrine loop of STAT3‐activating cytokines (preTh17). STAT3‐deficient AD‐HIES patients lack Th17‐ and Tfh17‐cells but retain preTh17‐ and Th1/17‐cells.
Giorgia Moschetti   +18 more
wiley   +1 more source

Lupus Panniculitis Immunoprofiling Reveals a Cytotoxic, Type 1‐Skewed T‐Cell Response With Signs of Metabolic Alteration

open access: yesAllergy, EarlyView.
Imaging mass cytometry shows lupus panniculitis lesions are dominated by cytotoxic and skin‐homing T cells with abundant macrophages and B‐cell aggregates. Spatial neighborhood analysis reveals organized leukocyte architecture, including B‐cell proximity to naïve T cells and M1 macrophages to cytotoxic T cells.
Milad Ameri   +11 more
wiley   +1 more source

Stat6 mediated gene regulation in eucariotic cells

open access: yes, 2001
Der Transkriptionsfaktor Stat6 vermittelt zentrale Wirkungen von IL-4 und IL-13, die in der Pathologie atopischer Erkrankungen eine Rolle spielen. Seine Spezifität für diese beiden allergieassoziierten Cytokine ist eine wesentliche Motivation ihn näher ...
Haake, Markus
core   +1 more source

Expression of Stat6 and pStat6 in the spleen.

open access: yes, 2014
A-D, Spleen sections from 8-week-old normal (left) and Ttc7fsn (right) mice stained with anti-Stat6 or anti-pStat6 (green), anti-CD4 (blue), and anti-IgM (red). Yellow indicates co-localization of B cells with Stat6.
Beth L. Hill (380277)   +1 more
core   +1 more source

Understanding the Type 2 Immunity: An Evolving View Beyond Allergic Diseases

open access: yesAllergy, EarlyView.
ABSTRACT Type 2 (T2) immunity is classically associated with defense against helminths and environmental threats, from a physiological perspective, and with allergies and eosinophilic inflammatory diseases, in a pathological sense. However, growing evidence reveals that T2 pathways also support other essential homeostatic functions, including tissue ...
Rodrigo Jiménez‐Saiz   +22 more
wiley   +1 more source

STAT6 degradation and ubiquitylated TRIML2 are essential for activation of human oncogenic herpesvirus.

open access: yesPLoS Pathogens, 2018
Aberrations in STAT6-mediated signaling are linked to the development of multiple cancer types. Increasing evidence has shown that activation of human oncogenic herpesvirus lytic replication is crucial for viral tumorigenesis.
Feng Gu   +12 more
doaj   +1 more source

Activation of the STAT6 transcription factor in Jurkat T-cells by the herpesvirus saimiri Tip protein

open access: yes, 2012
Herpesvirus saimiri (HVS), a T-lymphotropic monkey herpesvirus, induces fulminant T-cell lymphoma in non-natural primate hosts. In addition, it can immortalize human T-cells in vitro.
Joong-Kook Choi   +9 more
core   +1 more source

The Origins of Allergy: An Outside‐In, Bioenergetic Hypothesis

open access: yesAllergy, EarlyView.
ABSTRACT Allergic disease has risen too rapidly for inherited susceptibility to explain it, and the risk variants so far reported lie in the epithelial barrier and in type‐2 immunity. We propose a five‐layer model in which epithelial barrier and bioenergetic dysfunction may precede and promote type‐2 immune deviation rather than arise solely as its ...
Peter K. Smith   +9 more
wiley   +1 more source

SOX4-STAT6-MTHFD2 axis drives hepatocellular carcinoma progression and treatment resistance

open access: yesCell Death and Disease
Hepatocellular carcinoma (HCC) is a major global health burden. Despite recent advances in immunotherapy, tyrosine kinase inhibitors (TKIs) treatment or combined therapies, therapeutic resistance and disease progression remain significant challenges ...
Chia-Lung Tsai   +9 more
doaj   +1 more source

Home - About - Disclaimer - Privacy